Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | WNT3A | P56704 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776014 | 0.95 | GRM5 (0.40) | GRM5GSK3BDYRK1APTGS1PTGS2 | |
| SCHEMBL16776200 | 0.91 | FAAH (0.39) | KCNH2HRH3WNT3A | |
| SCHEMBL16776230 | 0.87 | PRMT5 (0.39) | GRM5GSK3BDYRK1APTGS1PTGS2 | |
| SCHEMBL16776124 | 0.87 | CNR2 (0.38) | GRM5GSK3BDYRK1APTGS1PTGS2 | |
| SCHEMBL16776232 | 0.85 | ABL1 (0.39) | PTGS1PTGS2ABL1 | |
| SCHEMBL16776477 | 0.85 | PTGS1 (0.40) | GSK3BPTGS1PTGS2NTRK1 | |
| SCHEMBL16776023 | 0.84 | GSK3B (0.36) | GSK3BDYRK1AABL1KCNH2HRH3 | |
| SCHEMBL16776209 | 0.84 | KCNH2 (0.42) | GSK3BABL1KCNH2HRH3POLB | |
| SCHEMBL16776280 | 0.84 | GSK3B (0.40) | GSK3BDYRK1APTGS1PTGS2ABL1 | |
| SCHEMBL16776053 | 0.83 | PTGS1 (0.42) | GRM5PTGS1PTGS2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GRM5 3471/4885GSK3B 1728/4885DYRK1A 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.